IXHL
NASDAQ · Pharmaceuticals
Incannex Healthcare Inc
$2.26
-0.01 (-0.44%)
Financial Highlights (FY 2026)
Revenue
939.6K
Net Income
-512,151,963
Gross Margin
48.2%
Profit Margin
-54,517.4%
Rev Growth
-46.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 48.2% | 48.2% | 52.4% | 52.4% |
| Operating Margin | -29,373.3% | -26,435.9% | 17.6% | 19.6% |
| Profit Margin | -54,517.4% | -51,791.6% | 19.2% | 18.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 939.6K | 1.77M | 25.07M | 24.10M |
| Gross Profit | 453.1K | 852.0K | 13.13M | 12.62M |
| Operating Income | -275,988,801 | -467,073,939 | 4.41M | 4.73M |
| Net Income | -512,151,963 | -866,748,339 | 4.81M | 4.53M |
| Gross Margin | 48.2% | 48.2% | 52.4% | 52.4% |
| Operating Margin | -29,373.3% | -26,435.9% | 17.6% | 19.6% |
| Profit Margin | -54,517.4% | -51,791.6% | 19.2% | 18.8% |
| Rev Growth | -46.8% | -46.8% | +16.3% | +6.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 30.57M | 31.96M |
| Total Equity | — | — | 43.10M | 45.37M |
| D/E Ratio | — | — | 0.71 | 0.70 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -273,253,339 | -488,135,900 | 6.46M | 6.22M |
| Free Cash Flow | — | — | 4.01M | 3.85M |